ea0028p52 | Clinical practice/governance and case reports | SFEBES2012
, Peacock Helen
, Arutchelvam Vijayaraman
, Nag Sath
, Ashwell Simon
Omnitrope is a biosimilar growth hormone (GH) preparation with a lower acquisition cost than other GH preparations. We switched adult patients with growth hormone deficiency treated with Genotropin (n=14, age 59.2±13.7 [mean±SD] yrs, 8 male) to Omnitrope at an equivalent dose. There followed titration visits every month for 3 months then visits every 3 months until 9 months. GH dose (0.5±0.0 vs 0.5±0.0 mg [mean±SD],...